The Centers for Disease Control and Prevention (CDC) has released clinical guidelines for the 2026–2027 respiratory virus season. Because of legal questions and ongoing inquiries, the CDC confirmed that the core COVID-19 vaccination recommendations set in July 2025 remain in effect for this season.
For people facing cancer or undergoing cancer treatments, staying up to date on COVID-19 protection remains a critical step in managing overall health.
What are the 2026–2027 clinical recommendations for COVID-19 vaccines?
The CDC guidance sets clear vaccination standards for adults and children across the United States for the current season. Because cancer treatments can weaken the body's immune system, the rules are specifically tailored to ensure vulnerable patients receive strong protection.
All adults (18 and Older): A 2026–2027 COVID-19 vaccine is recommended for all adults in the U.S.
Children with a weakened immune system (6 months to 17 years): A 2026–2027 COVID-19 vaccine is specifically recommended for all children in this age group who have moderate to severe immune system suppression, including children receiving cancer care.
Families of children without weakened immune systems can make an individual choice through shared decision-making with their pediatrician.
Important safety and age updates
The Food and Drug Administration (FDA) has updated product approvals for the 2026–2027 formulas:
Moderna (Spikevax): Now stands as the only FDA-approved COVID-19 vaccine available for young children aged 6 months through 4 years.
Pfizer-BioNTech: Is no longer authorized for children under 5 years old. However, it remains an option for older children, teens, and adults. It covers people under 65 only if they have at least 1 underlying condition that raises their risk of severe COVID-19.
Moderna (mNexspike): 65+ years; 12 – 64 years (and people with high-risk)
Novavax (Nuvaxovid): 65+ years; 12 – 64 years (and people with high-risk)
Because cancer treatments directly affect how well your body builds immunity, timing your vaccine is key. Patients with weakened immune systems may also be eligible for additional doses beyond the standard single shot to maintain protection throughout the year.
Questions to ask your oncology team
Always talk directly with your oncologist or healthcare provider to weigh the benefits and risks and create a personalized vaccination plan that fits your treatment schedule.
What is the best point in my chemotherapy or treatment cycle to get the 2026–2027 vaccine?
Based on my specific immune status, do I need additional vaccine doses this season?
Which approved vaccine brand is best suited for me or my child?
Should my family members and caregivers also get vaccinated to help protect me?
Stay updated with HealthTree
Keep track of your health and stay tuned with more community events, news and treatment advances updates with HealthTree. Create your personal health record and find personalized treatments, track your labs and contribute to patient-centered research.
Source: Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States
